semaglutide cardiovascular outcomes news 2025 Comparative of to dulaglutide in patients with type 2 diabetes semaglutide cardiovascular outcomes news 2025

For this study, we were interested in understanding on- and off-label drug prescribing patterns of newer GLP-1-based drugs approved for either T2DM or weight loss

For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes, said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health

Retatrutide Side Effects and What Clinical Research Shows So Far In clinical trials so far, Retatrutide has shown side effects similar to other incretin-based treatments

Recent Findings Newer generation GLP-1 based therapies have become more effective for the treatment of overweight and obesity, with data supporting tirzepatide as the most effective, followed by semaglutide and then liraglutide